Castle Biosciences First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Castle Biosciences (NASDAQ:CSTL) First Quarter 2025 Results

Key Financial Results

• Revenue: US$88.0m (up 21% from 1Q 2024).
• Net loss: US$25.8m (loss widened by US$23.3m from 1Q 2024).
• US$0.90 loss per share (further deteriorated from US$0.092 loss in 1Q 2024).

We've discovered 2 warning signs about Castle Biosciences. View them for free.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Castle Biosciences Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 9.5%. Earnings per share (EPS) missed analyst estimates significantly.

Looking ahead, revenue is forecast to grow 1.5% p.a. on average during the next 3 years, compared to a 7.0% growth forecast for the Healthcare industry in the US.

Performance of the American Healthcare industry.

The company's shares are down 17% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Castle Biosciences has 2 warning signs (and 1 which is a bit concerning) we think you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.